title: Breast enlargement during chronic antidepressant therapy.
abstract: Recent reports of mammoplasia during selective serotonin re-uptake inhibitor (SSRI) therapy suggested that this side effect may be more common than previously reported. We examined 59 women receiving > or = 2 months treatment with an SSRI or venlafaxine for changes in breast size in relation to menopausal status, weight gain and duration of drug therapy. Serum prolactin, estradiol and beta-hCG were also measured before and during treatment in a subgroup of patients. Twenty-three out of 59 patients (39%) reported some degree of mammoplasia. Significantly more SSRI vs. venlafaxine patients reported mammoplasia (p < 0.01). Eighty-four percent with mammoplasia had weight gain vs. 30% without mammoplasia (p < 0.001). The rate of mammoplasia was unrelated to age, menopausal status or duration of treatment. Serum prolactin increased during treatment in the paroxetine subgroup (p < 0.03). In conclusion, antidepressant-induced mammoplasia may be more common than previously expected.
authors.affiliation: Department of Psychiatry, University of Pennsylvania Medical Center, Philadelphia 19104, USA.
authors.forename: J D
authors.initials: JD
authors.lastname: Amsterdam
authors.forename: F
authors.initials: F
authors.lastname: Garcia-España
authors.forename: D
authors.initials: D
authors.lastname: Goodman
authors.forename: M
authors.initials: M
authors.lastname: Hooper
authors.forename: M
authors.initials: M
authors.lastname: Hornig-Rohan
mesh_terms: D001940:Breast / Q000473:pathology*; D001941:Breast Diseases / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology; D003511:Cyclohexanols / Q000009:adverse effects / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy*; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006965:Hyperplasia; D008297:Male; D008593:Menopause; D017374:Paroxetine / Q000009:adverse effects / Q000627:therapeutic use; D011388:Prolactin / Q000097:blood; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000069470:Venlafaxine Hydrochloride; D015430:Weight Gain
chemical_list: D003511:Cyclohexanols; D005473:Fluoxetine; D017374:Paroxetine; D011388:Prolactin; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride